Clinical and Quality of Life Outcomes Following Temperature-Controlled Radiofrequency Neurolysis of the Posterior Nasal Nerve (RhinAer) for Treatment of Chronic Rhinitis
Jivianne T. Lee,Gregory M. Abbas,Daniel D. Charous,PD Dr. med. Mandy Cuevas,Prof. Dr. med. Önder Göktas,Patricia A. Loftus,Nathan E. Nachlas,Elina M. Toskala,Jeremy P. Watkins,Prof. Dr. med. Detlef Brehmer
DOI: https://doi.org/10.1177/19458924221109987
2022-07-13
American Journal of Rhinology and Allergy
Abstract:American Journal of Rhinology &Allergy, Ahead of Print. BackgroundTemperature-controlled radiofrequency (TCRF) neurolysis of the posterior nasal nerve (PNN; RhinAer) is a minimally invasive treatment option for patients with chronic rhinitis.ObjectiveTo determine clinical outcomes and quality of life (QoL) following TCRF neurolysis of the PNN.MethodsA prospective single-arm study of 129 patients with chronic rhinitis at 16 medical centers in the United States and Germany.ResultsThe mean 24-h reflective total nasal symptom score (rTNSS) improved from 7.8 (95% CI, 7.5-8.1) at baseline to 3.6 (95% CI, 3.2-4.0) at 3 months and continued to improve to 2.9 (95% CI, 2.5-3.3) at 6 months (p < .001 comparing follow-up to baseline and p = .002 comparing 3 and 6 months). This represents 53.8% improvement over baseline at 3 months and 62.8% improvement at 6 months. Rhinorrhea, congestion, sneezing, and itching subscores and postnasal drip and cough scores were all significantly improved over baseline at both timepoints. At 3 months, 76.2% (95% CI, 68.1%-82.8%) of patients achieved a minimal clinically important difference of ≥30% improvement in rTNSS over baseline and the percentage was higher at 6 months (83.5% [95% CI, 75.8%-89.0%]). At 3 months, 80.3% (95% CI, 72.6%-86.3%) reported a minimal clinically important difference of ≥0.4-point improvement in the mini rhinoconjunctivitis quality of life questionnaire score, and the percentage was higher at 6 months; 87.7% (95% CI, 80.7%-92.4%). There were no serious adverse events with a relationship to the device/procedure reported through 6 months.ConclusionIn this large, multicenter study, TCRF neurolysis of the PNN was safe and resulted in a significant reduction in rhinitis symptom burden at 3 months that was sustained/improved through 6 months. The majority of patients reported a clinically relevant improvement in QoL at 3 and 6 months postprocedure.
otorhinolaryngology